Grupo SOMAR to Invest 202 Million Pesos in 2025 to Expand Pharmaceutical Capacity in the State of Mexico

Grupo SOMAR, a company dedicated to the development, manufacturing, and commercialization of pharmaceutical products, announced a 202 million peso investment in 2025 to expand production capacity at its two facilities in the State of Mexico, creating 260 jobs.

The company, which produces analgesics, antibiotics, supplements, and specialized treatments for the domestic market, aims to increase supply for Walmart, Costco, Farmacias del Ahorro, Farmacias Similares, among others, as well as for its own brands: Advaita Pharmaceuticals, Laboratorios Serral, and Lakeside.

202 Million Peso Investment in SOMAR Plants in the State of Mexico

As part of the investment, the Chalco facility—the largest in the country—will add two new effervescent production lines and one oral solid dosage line, with an allocation of 160 million pesos. Meanwhile, the Naucalpan plant will install a new softgel capsule line for various uses and undergo general infrastructure upgrades and operational improvements, representing an investment of 42 million pesos.

Strengthening Supply and Logistics Capabilities

Through this expansion, the pharmaceutical company seeks to meet the growing demand of the healthcare sector and ensure a stronger supply of medicines in the domestic market. The strategy, focused on boosting production, also aims to reinforce distribution networks to guarantee the timely availability of treatments across major retail chains and pharmacies nationwide.

The announcement also reinforces Grupo SOMAR’s presence in the State of Mexico, where the pharmaceutical sector plays a key role in economic development and the creation of specialized jobs. The company emphasized its ongoing commitment to exploring new opportunities to strengthen its production capacity and expand its portfolio of solutions for patients in Mexico.